Literature DB >> 23312373

Mechanisms underlying current and future anti-obesity drugs.

Roger A H Adan1.   

Abstract

Regulation of body weight is organized by distributed brain circuits that use a variety of neuropeptides and transmitters, and that are responsive to endocrine and metabolic signals. Targeting of these circuits with novel pharmaceutical drugs would be helpful additions to lifestyle interventions for the treatment of obesity. The recent FDA approval of two anti-obesity drugs holds promise in a field in which previous drugs were removed from clinical use because of unacceptable psychiatric and cardiovascular side effects. Here, the modes of action of anti-obesity drugs are reviewed.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23312373     DOI: 10.1016/j.tins.2012.12.001

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  26 in total

1.  Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

Review 3.  Pharmacological treatment and therapeutic perspectives of metabolic syndrome.

Authors:  Soo Lim; Robert H Eckel
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

4.  A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes.

Authors:  Dongsheng Cai; Sudarshana Purkayastha
Journal:  Drug Discov Today Dis Mech       Date:  2013-06-01

5.  Resveratrol treatment rescues hyperleptinemia and improves hypothalamic leptin signaling programmed by maternal high-fat diet in rats.

Authors:  J G Franco; C P Dias-Rocha; T P Fernandes; L Albuquerque Maia; P C Lisboa; E G Moura; C C Pazos-Moura; I H Trevenzoli
Journal:  Eur J Nutr       Date:  2015-03-24       Impact factor: 5.614

6.  Absence of intracellular ion channels TPC1 and TPC2 leads to mature-onset obesity in male mice, due to impaired lipid availability for thermogenesis in brown adipose tissue.

Authors:  Pamela V Lear; David González-Touceda; Begoña Porteiro Couto; Patricia Viaño; Vanessa Guymer; Elena Remzova; Ruth Tunn; Annapurna Chalasani; Tomás García-Caballero; Iain P Hargreaves; Patricia W Tynan; Helen C Christian; Rubén Nogueiras; John Parrington; Carlos Diéguez
Journal:  Endocrinology       Date:  2014-12-29       Impact factor: 4.736

Review 7.  The use of the reinstatement model to study relapse to palatable food seeking during dieting.

Authors:  Donna J Calu; Yu-Wei Chen; Alex B Kawa; Sunila G Nair; Yavin Shaham
Journal:  Neuropharmacology       Date:  2013-05-06       Impact factor: 5.250

8.  Adiponectin homolog osmotin, a potential anti-obesity compound, suppresses abdominal fat accumulation in C57BL/6 mice on high-fat diet and in 3T3-L1 adipocytes.

Authors:  Min Gi Jo; Min Woo Kim; Myeung Hoon Jo; Noman Bin Abid; Myeong Ok Kim
Journal:  Int J Obes (Lond)       Date:  2019-06-04       Impact factor: 5.095

9.  Striatal dopamine homeostasis is altered in mice following Roux-en-Y gastric bypass surgery.

Authors:  India A Reddy; David H Wasserman; Julio E Ayala; Alyssa H Hasty; Naji N Abumrad; Aurelio Galli
Journal:  ACS Chem Neurosci       Date:  2014-08-05       Impact factor: 4.418

10.  14-3-3ζ coordinates adipogenesis of visceral fat.

Authors:  Gareth E Lim; Tobias Albrecht; Micah Piske; Karnjit Sarai; Jason T C Lee; Hayley S Ramshaw; Sunita Sinha; Mark A Guthridge; Amparo Acker-Palmer; Angel F Lopez; Susanne M Clee; Corey Nislow; James D Johnson
Journal:  Nat Commun       Date:  2015-07-29       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.